Home Cart Sign in  
Chemical Structure| 2169919-21-3 Chemical Structure| 2169919-21-3

Structure of Revumenib
CAS No.: 2169919-21-3

Chemical Structure| 2169919-21-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Revumenib (SNDX-5613) is an effective and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM. In cellular experiments, it inhibits Menin-MLL with an IC50 of 10-20 nM. Revumenib can be utilized in research on acute leukemia with MLL gene rearrangements, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Synonyms: SNDX-5613

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Revumenib

CAS No. :2169919-21-3
Formula : C32H47FN6O4S
M.W : 630.82
SMILES Code : C(N1CCC2(CN(C2)C=3C(OC4=C(C(N(C(C)C)CC)=O)C=C(F)C=C4)=CN=CN3)CC1)[C@@H]5CC[C@@H](NS(CC)(=O)=O)CC5
Synonyms :
SNDX-5613
MDL No. :MFCD32701940

Safety of Revumenib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Revumenib

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
KMT2A-rearranged ALL cell lines (SEM, RS4;11) up to 10 µM 10 weeks Induced acquired resistance, some cell lines acquired MEN1 mutations Int J Mol Sci. 2024 May 30;25(11):6020
Primary NUP98::NSD1 and NUP98::TOP1 AML cells 2.5 to 2500 nM 14 days To evaluate the effect of Revumenib on the proliferation and differentiation of primary AML cells, results showed that Revumenib suppressed cell proliferation and induced myeloid differentiation in a dose-dependent manner. Hemasphere. 2023 Jul 27;7(8):e935
KMT2A-rearranged ALL cell lines 0.031 µM to 0.125 µM (IC50) 4 days Assessed cell viability, showed high sensitivity Int J Mol Sci. 2024 May 30;25(11):6020
KMT2A-rearranged AML cell lines up to 3 µM 4 days Assessed cell viability, most cell lines did not reach IC50 values Int J Mol Sci. 2024 May 30;25(11):6020
HL-60 cells 50 nM 72 hours No significant apoptosis or CD11b induction observed Cancers (Basel). 2024 Mar 28;16(7):1311
OCI-AML3 cells 50 nM 72 hours Increased CD11b expression (combination 5.1-fold) and apoptosis rates (combination 37.8%) Cancers (Basel). 2024 Mar 28;16(7):1311
MOLM13 cells 50 nM 72 hours Marked increase in CD11b expression (combination 6.6-fold vs DMSO 1.2-fold), no significant apoptosis Cancers (Basel). 2024 Mar 28;16(7):1311
MV4:11 cells 50 nM 72 hours Significant synergistic apoptosis induction (combination 79.9% vs control 10.1%) Cancers (Basel). 2024 Mar 28;16(7):1311

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice NUP98::NSD1 FLT3-ITD-positive AML PDX model Oral 0.033% or 0.1% Revumenib Continuous administration To evaluate the antileukemic activity of Revumenib in a PDX model, results showed that Revumenib completely eradicated leukemic cells and prolonged the survival of mice. Hemasphere. 2023 Jul 27;7(8):e935

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05918913 Relapsed/Refractory Acute Leuk... More >>emia Less << AVAILABLE - Alabama Center for Childhood C... More >>ancer And Blood Disorders, Children's of Alabama, Birmingham, Alabama, 35233, United States|Phoenix Children's Hospital, Phoenix, Arizona, 85016, United States|City of Hope, Duarte, California, 91010, United States|City of Hope at Orange County Lennar Foundation Cancer Center, Irvine, California, 92618, United States|UCLA, UCLA RRMC, Drug Information Center, Department of Pharmaceutical Services Drug Supply Shipment, Los Angeles, California, 90095, United States|Lucile Packard Children's Hospital-Stanford, Palo Alto, California, 94304, United States|Rady Children's Hospital, San Diego, California, 92123, United States|University of California, San Francisco, San Francisco, California, 94158, United States|Center for Cancer and Blood Disorders, Colorado Children's Hospital, Aurora, Colorado, 80045, United States|HCTU, Division of Hematology, University of Colorado, Anschutz Medical Center, Aurora, Colorado, 80045, United States|Advent Health Orlando, Orlando, Florida, 32804, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, 30322, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, 30322, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|Children's Hospital, New Orleans, Louisiana, 70118, United States|Dana-Farber Cancer Institute, Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, 02215, United States|Children's Mercy Hospital-Kansas City, Kansas City, Missouri, 64108, United States|Siteman Cancer Center - Washington University, Saint Louis, Missouri, 63110, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|Memorial Sloan Kettering Cancer Center, Long Island City, New York, 10065, United States|Duke University Medical Center, Durham, North Carolina, 27705, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Division of Hematology and Oncology, Division of Pulmonary, Critical Care and Sleep Medicine, Vontz Center for Molecular Studies, Cincinnati, Ohio, 45267, United States|OSU Medical Center, Columbus, Ohio, 43210, United States|Doernbecher Children's Hospital, Oregon Health & Science University, Portland, Oregon, 97239, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Memorial Hermann-Texas Medical Center, Houston, Texas, 77030, United States|Texas Children's Hospital, Houston, Texas, 77030, United States|Division of Hematology and Hematologic Malignancies, University of Utah-Huntsman Cancer Hospital, Salt Lake City, Utah, 84112, United States|Seattle Children's Research Institute, Seattle Childrens Hospital, Seattle, Washington, 98105, United States Less <<
NCT06229912 Leukemia|HOX Gene PHASE2 RECRUITING 2028-12-01 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States Less <<
NCT05406817 Acute Leukemia PHASE1 COMPLETED 2024-11-18 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.59mL

0.32mL

0.16mL

7.93mL

1.59mL

0.79mL

15.85mL

3.17mL

1.59mL

 

Historical Records

Categories